Appili Therapeutics Inc. (APLI.H)

الملف الشخصي

https://appilitherapeutics.com

Appili Therapeutics Inc. is a Canadian biopharmaceutical company focused on developing treatments for infectious diseases and medical countermeasures. Its current portfolio includes LIKMEZ, a liquid oral formulation of metronidazole designed for anaerobic bacterial and protozoal infections, as well as ATI-1801, a topical paromomycin formulation under development for cutaneous leishmaniasis. The company is also advancing ATI-1701, a live-attenuated vaccine candidate, and working with Vitalex Biosciences on VXV-01, a dual-antigen vaccine program targeting invasive Candida infections. Based in Halifax, Nova Scotia, Appili Therapeutics concentrates on anti-infective products that address unmet clinical needs in the United States and Canada.